-
-
-
-
-
-
-
Actinium Pharma (ATNM) Highlights Expanded Data Set for ATNM-400
-
-
-
-
-
-
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
-
-
-
-
-
-
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
-
-
-
-
-
-
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
-
-
-
-
-
-
-
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
-
-
-
-
-
-
-
Actinium Pharma (ATNM) Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Actinium Pharma (ATNM)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

